3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
8
NIH
2
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Interventions
pembrolizumab
184
Carboplatin
132
Cisplatin
102
Paclitaxel
101
Gemcitabine
86
Pemetrexed
79
durvalumab
75
Nivolumab
67
Docetaxel
55
atezolizumab
51
Cyclophosphamide
49
Bevacizumab
49
Dexamethasone
45
Capecitabine
45
Oxaliplatin
42
130-nm albumin-bound paclitaxel
41
Rituximab
40
Fulvestrant
39
Lenalidomide
38
Fluorouracil
37
Prednisone
32
osimertinib
31
olaparib
29
venetoclax
28
fludarabine
28
Leucovorin
28
Trastuzumab
27
Doxorubicin
27
Etoposide
25
Cetuximab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
INDUSTRY
×
Tomography, X-Ray Computed
×
Clear all
NCT05117840
2026-04-30
SHIELD
Guardant Health, Inc.
Active not recruiting
12,000 enrolled